Rejected from NEJM? The 7 Best Journals to Submit Next

Understanding NEJM's editorial priorities helps you pick a better target. NEJM isn't just looking for great science. It's looking for science that will change how doctors practice medicine tomorrow morning.

The editorial bar

Practice-changing potential. NEJM wants papers that will immediately alter clinical decision-making for a wide audience of physicians. A well-designed trial showing marginal improvement over existing treatments usually won't clear this bar. The editors ask: "Will a cardiologist, a primary care doctor, and an endocrinologist all need to read this?"

Large-scale evidence. NEJM favors large randomized controlled trials, landmark cohort studies, and definitive evidence syntheses. Pilot studies, small sample sizes, and single-center trials rarely survive the initial screen, regardless of the findings.

Novelty in a high-stakes area. NEJM publishes across all of medicine, but the journal gravitates toward high-mortality, high-morbidity conditions where new evidence has the greatest patient impact. Cancer, cardiovascular disease, infectious disease, and immunology dominate the table of contents for a reason.

Clean methodology. NEJM's statistical reviewers are among the most rigorous in medical publishing. Composite endpoints that inflate effect sizes, subgroup analyses presented as primary findings, and missing data handled improperly will all trigger rejection.

Common rejection scenarios

"The findings don't represent a sufficient advance." This is NEJM's most common desk rejection language. Your trial might be well-designed and statistically significant, but the clinical effect size isn't large enough to change practice. This doesn't mean the paper is bad. It means NEJM's threshold for "advance" is extremely high.

"We have a surplus of papers on this topic." NEJM receives dozens of submissions on popular topics like checkpoint inhibitors, GLP-1 agonists, and mRNA therapeutics every week. Even strong papers get rejected simply because the journal can't publish them all.

"The study design doesn't support the conclusions." NEJM's peer reviewers scrutinize the gap between what the data actually show and what the discussion claims. Overstating results in an observational study, or drawing causal conclusions from correlational data, is a fast path to rejection.

"More appropriate for a specialty audience." NEJM is a general medical journal. A highly specialized study in pediatric nephrology or neuro-ophthalmology might be excellent, but NEJM will redirect you toward a specialty journal where the audience is better matched.

1. The Lancet

The Lancet is NEJM's closest competitor in every measurable dimension: IF, readership, prestige, and editorial selectivity. If NEJM rejected your paper on timing or topic saturation rather than quality, The Lancet is the most logical next submission. The two journals share similar standards for evidence scale and clinical impact, but The Lancet places slightly more emphasis on global health equity and social determinants of health.

One difference worth knowing: The Lancet is more willing to publish research with policy implications even when the direct clinical application isn't immediate. If your paper connects clinical findings to health systems or population-level outcomes, that's a strength at The Lancet.

Best for: Large clinical trials with global health implications, public health intervention studies, research at the intersection of medicine and policy.

2. JAMA

JAMA is the strongest alternative for clinical research with a North American focus. While NEJM and The Lancet both position themselves as global journals, JAMA's readership is predominantly US-based. Research relevant to US healthcare delivery, FDA-regulated therapies, and American clinical practice guidelines finds a natural audience at JAMA.

JAMA also has a strong network of specialty journals (JAMA Oncology, JAMA Cardiology, JAMA Internal Medicine), and editors sometimes suggest transfers. This means a single submission can potentially reach the right audience even if the main journal declines.

Best for: US-focused clinical trials, health services research, studies relevant to US insurance and policy contexts.

3. The BMJ

The BMJ publishes clinical medicine with a strong emphasis on evidence-based practice and transparent reporting. If NEJM rejected your paper because the effect size was modest but real, The BMJ might value it differently. The BMJ publishes more negative trials and "boring but important" confirmatory research than NEJM does.

The BMJ's open peer review system means reviewers sign their names, which tends to produce more constructive and specific feedback. If you're anticipating another round of revisions, The BMJ's review culture can actually help strengthen your paper.

Best for: Evidence-based medicine, randomized trials (including negative results), systematic reviews, research with UK or Commonwealth healthcare relevance.

4. Annals of Internal Medicine

Annals is the American College of Physicians' journal, and it publishes research that informs internal medicine practice and clinical guidelines. If NEJM rejected your paper for being "too specialized" within internal medicine, Annals might see that specialization as a strength.

Annals publishes the ACP clinical guidelines and clinical practice reviews, so papers with guideline-informing potential carry extra weight here. Systematic reviews and evidence assessments are particularly well-suited.

Best for: Internal medicine research, clinical guidelines, screening and prevention studies, diagnostic accuracy research.

5. NEJM Evidence

NEJM Evidence launched in 2022 as NEJM's companion journal for clinical research that meets high methodological standards but doesn't quite reach the main journal's threshold for broad impact. Think of it as the same editorial rigor with a wider aperture for what gets published.

The journal accepts more specialized clinical trials, translational studies, and research that advances understanding within a specific disease area. If NEJM's rejection said "sound but not broadly impactful," NEJM Evidence is the most direct path to publication within the same publisher.

Best for: Well-designed clinical trials that are too specialized for the main NEJM, translational research, clinical studies with solid methodology but narrower scope.

6. JAMA Network Open

JAMA Network Open is the broad-scope, open-access journal in the JAMA family. It accepts about 15% of submissions, which is much more accessible than NEJM or JAMA, while still maintaining the JAMA brand and editorial standards. The open-access format means your paper gets immediate, unrestricted global visibility.

For papers that NEJM rejected on scope or impact grounds, JAMA Network Open provides a path that preserves the prestige of the JAMA name. The APC is $3,000, so check whether your institution has a Read and Publish agreement.

Best for: Sound clinical research across all specialties, health services research, studies benefiting from open-access global reach.

7. PLOS Medicine

PLOS Medicine is the top open-access general medical journal. It shares NEJM's commitment to methodological rigor but is more willing to publish research with public health and policy dimensions that NEJM might consider outside its clinical focus.

PLOS Medicine also publishes research essays, policy forums, and other formats that traditional clinical journals typically don't. If your paper has a strong public health or policy component that NEJM didn't value, PLOS Medicine has more room for that content.

Best for: Global health research, evidence synthesis with policy implications, health equity studies, public health interventions.

Large clinical trial rejected at the desk? Try The Lancet or JAMA depending on geographic scope. If both are too selective, NEJM Evidence or JAMA Network Open are strong backup options.

Specialty-focused trial rejected? Annals of Internal Medicine is strong for internal medicine. For other specialties, consider JAMA Oncology (IF ~20), JAMA Cardiology (IF ~14), or the top journal in your specific field.

Observational study rejected? NEJM rarely publishes observational studies unless they're enormous and practice-changing. The BMJ, PLOS Medicine, and JAMA Network Open are all more receptive to well-designed observational research.

Rejected after peer review? Address every reviewer comment before resubmitting. The Lancet, JAMA, and The BMJ may ask about prior review history. Having detailed, addressed reviewer feedback can actually speed up review at your next target.

Recalibrate your framing. NEJM wants "this changes everything." Other journals want "this is solid evidence that advances what we know." Tone down the claim to match the evidence, and match the framing to your target journal's expectations.

Strengthen your cover letter. Each journal has different priorities. A cover letter that worked for NEJM (emphasizing practice-changing potential) might not work for PLOS Medicine (which wants global health relevance) or Annals (which wants guideline-informing potential). Rewrite the letter for each target.

Check your reporting compliance. CONSORT for trials, STROBE for observational studies, PRISMA for reviews. NEJM checks these rigorously, but if your rejection was at the desk, you might not have received specific feedback on compliance gaps. Fix them proactively.

Get an outside perspective on scope. The most common reason good papers fail at NEJM is scope mismatch. Ask a colleague outside your specialty whether your paper reads as "important for all doctors" or "important for specialists in my field." The honest answer determines your journal target.

Run your manuscript through a free Manusights scan to check formatting, reporting compliance, and scope alignment before your next submission. A quick check can catch the issues that trigger desk rejections, saving you weeks of wasted review time.